MM-302

liposomal doxorubicin (HER2-targeted) · Merrimack Pharmaceuticals

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MM-302, covering 2017-01-06 to 2017-05-04. Get the full timeline:

Most recent: Clinical Trial Update: 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets [EARLY_Phase 1]